SSR180711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.[3][4]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H21BrN2O2 |
| Molar mass | 329.238 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
References
edit- ^ Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, et al. (January 2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology. 32 (1): 17–34. doi:10.1038/sj.npp.1301188. PMID 16936709.
- ^ Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, et al. (January 2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology. 32 (1): 1–16. doi:10.1038/sj.npp.1301189. PMID 17019409.
- ^ Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. (January 2008). "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry. 63 (1): 92–7. doi:10.1016/j.biopsych.2007.04.034. PMID 17601496.
- ^ Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I (June 2009). "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia" (PDF). Neuropsychopharmacology. 34 (7): 1753–63. CiteSeerX 10.1.1.470.1879. doi:10.1038/npp.2008.232. PMID 19158670. S2CID 827363.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |